Eva Kubala Havrdova
Overview
Explore the profile of Eva Kubala Havrdova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hill M, Kancheva R, Velikova M, Kanceva L, Vcelak J, Ampapa R, et al.
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076462
Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the central nervous system. The manifestation of MS is related to steroid changes during the menstrual cycle and pregnancy. As...
2.
Dhondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, et al.
Comput Methods Programs Biomed
. 2025 Feb;
263:108624.
PMID: 39965473
Background: Prognostic machine learning research in multiple sclerosis has been mainly focusing on black-box models predicting whether a patients' disability will progress in a fixed number of years. However, as...
3.
Muller J, Sharmin S, Lorscheider J, Horakova D, Kubala Havrdova E, Eichau S, et al.
CNS Drugs
. 2025 Feb;
39(4):403-416.
PMID: 39953338
Background: In relapsing-remitting multiple sclerosis (RRMS), extended exposure to high-efficacy disease modifying therapy may increase the risk of side effects, compromise treatment adherence, and inflate medical costs. Treatment de-escalation, here...
4.
Jiraskova Zakostelska Z, Kraus M, Coufal S, Prochazkova P, Slavickova Z, Thon T, et al.
Front Immunol
. 2024 Dec;
15:1475126.
PMID: 39737164
The gut microbiota influences the reactivity of the immune system, and has emerged as an anti-inflammatory commensal. Here, we investigated whether its lysate could prevent severe forms of neuroinflammation in...
5.
Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, et al.
Neurodegener Dis Manag
. 2024 Dec;
14(6):193-201.
PMID: 39676554
No abstract available.
6.
Kancheva R, Hill M, Velikova M, Kancheva L, Vcelak J, Ampapa R, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596101
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) mainly afflicting young women. Various steroids can influence the onset and development of the disease or,...
7.
Lorincz B, Vrablik M, Murali R, Kubala Havrdova E, Horakova D, Krasensky J, et al.
Acta Neurol Belg
. 2024 Oct;
124(6):1981-1988.
PMID: 39455532
Objectives: This study aimed to investigate relationships between cholesterol profile, brain volumetric MRI, and clinical measures in a large observational cohort of multiple sclerosis (MS) patients. Materials And Methods: We...
8.
Portaccio E, Magyari M, Kubala Havrdova E, Ruet A, Brochet B, Scalfari A, et al.
Lancet Reg Health Eur
. 2024 Oct;
44:100977.
PMID: 39444703
Multiple sclerosis is a chronic, inflammatory, and neurodegenerative disease of the central nervous system and a major cause of neurological disability in young adults. Its prevalence and incidence are increasing,...
9.
Yeh W, van der Walt A, Skibina O, Kalincik T, Alroughani R, Kermode A, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Oct;
11(6):e200328.
PMID: 39442037
Background And Objectives: Women with multiple sclerosis (MS) are at risk of disease reactivation in the early postpartum period. Ocrelizumab (OCR) is an anti-CD20 therapy highly effective at reducing MS...
10.
Montalban X, Vermersch P, Arnold D, Bar-Or A, Cree B, Cross A, et al.
Lancet Neurol
. 2024 Sep;
23(11):1119-1132.
PMID: 39307151
Background: Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown preliminary efficacy in people with relapsing multiple sclerosis in a phase 2 trial. Here, we aimed to compare the safety...